Skip to main content
. 2023 Oct 2;6(10):e2336604. doi: 10.1001/jamanetworkopen.2023.36604

Figure 2. Standardized 5-Year Overall Survival for Men With De Novo Metastatic Castration-Sensitive Prostate Cancer Diagnosed in 2008-2020.

Figure 2.

Overall survival was estimated using a flexible parametric model standardized for baseline clinical characteristics according to last calendar period (2017-2020). Five-year restricted mean survival (RMS) was used to describe the increase in survival time. Survival estimates and 95% CI are also reported in eTable 1 in Supplement 1. Numbers at risk were extracted from the unadjusted analysis.